Introduction {#Sec1}
============

Stroke continues to be a major cause of death in the USA and throughout the world. Due to treatment options for stroke being limited to tissue plasminogen activator (tPA), a surge in novel therapies, such as stem cell transplantation, has been explored in the laboratory. Over the last decade, stem cell therapy has shown promise as an experimental treatment for stroke \[[@CR1]--[@CR3]\]. The first clinical trial implementing cell therapy as a treatment for stroke occurred in 1998 \[[@CR4]\]. In the last 2 years, the US Food and Drug Administration (FDA) has approved limited clinical trials of cell therapy in stroke patients. Bone marrow-derived stem and progenitor cells represent a major donor cell source for transplantation. Along the lines of stroke treatment academic industry roundtable (STAIR) recommendations for translating pharmacologics from the laboratory to the clinic, the stem cell therapeutics as an emerging paradigm for stroke (STEPS) has been advanced as a guiding principle for cell therapy in stroke. Here, we discuss preclinical studies of cell transplantation in experimental stroke with emphasis on bone marrow-derived stem cells using STEPS as a yardstick in building the efficacy and safety profile of this cell therapy for clinical application.

The Many Faces of Bone Marrow-Derived Stem Cells {#Sec2}
================================================

The bone marrow consists of a heterogeneous population of stem cells, namely hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) \[[@CR5]\]. Endothelial progenitor cells (EPCs) and very small embryonic-like stem cells (VSELs) have also been isolated from the bone marrow. Previous studies have discussed the potential of bone marrow-derived stem cells to differentiate into neurons in vitro \[[@CR6]\], and their secretion of growth factors crucial to neuronal survival \[[@CR7]--[@CR9]\]. Interest in utilizing bone marrow-derived stem cells as a therapy for stroke has increased as researchers look to cell therapy as a treatment for stroke.

A central characteristic of HSCs is their ability to repopulate removed bone marrow \[[@CR10]\]. HSCs remain quiescent and low in number during homeostasis, but can quickly proliferate and become mobile in response to injury \[[@CR11]--[@CR13]\]. The SDF-1/CXCR4 chemoattractant pathway is crucial for HSC mobilization and migration. Activation of this pathway stimulates the migration of HSCs from the bone marrow into the circulation \[[@CR14]\].

Mesenchymal stem cells were first defined as a population of plastic-adherent fibroblastic cells isolated by Percoll density centrifugation \[[@CR15]\]. Human MSCs do not express the hematopoietic surface markers CD34 and CD45, but they do express CD13, Stro-1, CD105 (SH2), and SH3. The therapeutic potential of MSCs lies in their ability to differentiate into mesodermal lineages, such as skeletal myoblasts, fibroblasts, osteoblasts, adipocytes, and chondroblasts both in vitro and in vivo \[[@CR16]--[@CR20]\] (Table [1](#Tab1){ref-type="table"}). MSCs utilized in experimental stroke models have improved the functional recovery of neurological deficits caused by cerebral ischemia \[[@CR49]--[@CR58]\]. Clinical reports of MSC transplantation in stroke patients reveal that MSCs may improve the functional recovery of patients without adverse side effects \[[@CR49]\]. The underlying therapeutic mechanism through which MSCs offer therapeutic benefit remains unclear.Table 1Target diseases and phenotypes of EPCs, MSCs, hTERT-MSCs, HSCs, and VSEL cellsBM cellsTarget diseasePhenotypeReferencesEPCsRetinal ischemia, Parkinson's disease, malignant tumors, chronic obstructive, pulmonary disease, ischemic stroke, traumatic brain injury, and Alzheimer's diseaseEndothelial cells\[[@CR21]--[@CR31]\]MSCsMalignant tumors and cancer, inflammation, autoimmune, asthma, neurological damage and regeneration (stroke, Alzheimer, Parkinson, traumatic brain injury, spinal cord injury), cardiac-related disease (i.e., ischemic cardiomyopathy, myocardial infarction), inflammatory bowel, multiple sclerosis, and liver regenerationOCA cells\[[@CR32]--[@CR35]\]OCA cells\[[@CR36], [@CR37]\]OCA cells\[[@CR18]\]OCA cells\[[@CR38]--[@CR40]\]OCA cells\[[@CR41], [@CR42]\]OCA cells\[[@CR43]--[@CR45]\]hTERT-MSCsCerebral ischemia and spinal cord injuryOCA cells\[[@CR42]\]HSCsAlzheimer's disease, traumatic brain injury, myeloid leukemia, sickle cell anemia, and cutaneous repairCD34+ and CXCR4+\[[@CR10]--[@CR13]\]VSEL CellsTissue rejuvenation, stroke, myocardial infractions, diabetes, and cutaneous repairTree germ lineages\[[@CR46]--[@CR48]\]*OCA cells* osteogenic, chondrogenic, and adipogenic cells

Very small embryonic-like cells are present in many adult organs expressing progenitor stem cell markers \[[@CR46]\]. The brain contains a relatively high number of cells that display the VSEL phenotype \[[@CR47], [@CR59]\]. VSELs are smaller than erythrocytes and can be purified from umbilical cord blood and mobilized peripheral blood. VSELs are recognized as very small cells belonging to the non-hematopoietic portion of leukocytes, expressing CD34, CD133, and CXCR4 antigens \[[@CR46], [@CR48]\] and are mobilized into the peripheral blood following injury.

EPCs are immature endothelial cells circulating in the peripheral blood. EPCs are an important component of the vascular system, as they mature into endothelial cells \[[@CR21]--[@CR25]\]. Asahara and colleagues transplanted EPCs isolated from human umbilical cord blood into animal models of ischemia. The transplanted EPCs were found in the endothelium of newly formed vessels in the ischemic regions \[[@CR21]\]. EPCs are hematopoietic in origin and can be found in the peripheral blood of adults and can also be isolated from human umbilical cord blood \[[@CR60], [@CR61]\]. Both animal and human studies suggest that EPCs principally participate in re-endothelialization during the neovascularization of ischemic organs. These findings suggest that EPC modulation can be focused toward the therapy of cerebrovascular diseases \[[@CR21], [@CR22], [@CR25], [@CR26], [@CR61], [@CR62]\] (Table [1](#Tab1){ref-type="table"}).

HSCs, MSCs, and VSELs can all be categorized as donor cells primarily aimed toward rescuing the stroke damaged cells and ischemic cells within the parenchyma. While rescuing the ischemic penumbra is important, these cells do not address the issue of the damaged microvasculature. To this end, EPCs are unique in that they target the leaky vasculature. By repairing the broken blood brain barrier (BBB), EPCs may aid in the recovery from stroke and abrogate the immunological attack on the brain and its microvasculature (Fig. [1](#Fig1){ref-type="fig"}). Due to their ability to differentiate into endothelial cells, EPCs may be the ideal choice for cell transplantation in BBB repair.Fig. 1BBB repair via EPC transplantation post-ischemic injury. Under normal conditions, the BBB is intact (**a**). The integrity of the BBB becomes compromised after stroke, allowing immune cells to enter the brain parenchyma (**b**). EPCs migrate from the periphery to the site of injury (**c**). Once at the area of injured vasculature, the EPCs aid in repairing the compromised BBB, potentially attenuating stroke pathogenesis (**d**)

Due to laboratory findings suggesting the angiogenic and vasculogenic potential of EPCs, clinical studies have been initiated to determine if patients with ischemic events may benefit from EPC administration \[[@CR63]\]. Studies have also been initiated to determine if patients with lower numbers of EPCs are at an increased risk of atherosclerotic events. Here, we discuss the therapeutic potential of EPCs, as well as the hurdles faced when translating EPC therapy from the laboratory to the clinic.

Crossing the Great Divide: Cell Therapy at the Crossroad of Laboratory and Clinic {#Sec3}
=================================================================================

Our team together with stem cell-based stakeholders from academic and industry, as well as federal agencies such as NIH and FDA, has supported the STEPS consortium in an effort to improve the successful translation of cell therapy in stroke from the laboratory to the clinic \[[@CR3]\]. Both clinicians and researchers acknowledge that no two strokes are the same, underscoring the heterogeneity of the disease. Although ischemic stroke is the target of cell therapy over hemorrhagic stroke, ischemic stroke is plagued with several subtypes ranging from infarcted brain areas to cell death mechanisms. Only recently have laboratory studies attempted to encompass these various strokes in animal models \[[@CR64]\]. The most commonly used model for stroke is focal ischemia in rats or mice. The cell death pathways and damaged brain regions after focal ischemia can be manipulated by using permanent, transient, proximal, or distal occlusion/ligation of the middle cerebral artery. In an effort to study the heterogeneity of stroke, multiple strains, age, gender, varying stroke severity, and at least two focal ischemia models should be utilized in the laboratory to test the safety and efficacy of cell therapy \[[@CR1], [@CR3]\]. Testing cell therapy in a larger, non-human primate model may be needed due to the white matter injury associated with stroke \[[@CR3], [@CR65]--[@CR67]\], which is not well characterized in the rodent model (Fig. [2](#Fig2){ref-type="fig"}). Other transplantation regimen issues, such as donor cell size which may cause microembolism, and toxicology readouts which may be better studied in a non-human primate model, may similarly necessitate testing of cell therapy in large animal model.Fig. 2Translational steps from the laboratory to the clinic. Two focal ischemia models in rodents should be utilized to determine optimal timing, dose, and route of administration. Functional recovery should also be tested in the rodent models. Once these factors have been established in the rodent models, the cell therapy may require further validation in a larger animal model, especially when critical stroke readouts (e.g., white matter) cannot be determined in the rodents. Limited clinical trials may proceed in tandem with the preclinical studies once safety profile and efficacy outcomes are demonstrated in the laboratory

Route of administration is also an important factor that needs to be taken into consideration when translating cell therapy from the laboratory to the clinic. Although intravenous (IV) cell delivery is a minimally invasive procedure, it is traditionally only employed in acute stroke models, limiting the population that may benefit from cell therapy. IV cell transplantation requires a higher cell dose, which may cause the formation of microembolisms. Intra-arterial (IA) cell delivery is also minimally invasive, but is typically only employed in acute stroke models to take advantage of the stroke-induced upregulation of chemoattractant pathways that aid in the migration of stem cells from the periphery to the brain. IA cell delivery may circumvent the formation of microembolisms by requiring a lower cell dose. Intracerebral (IC) cell transplantation can be employed in both the acute and chronic stages of stroke. However, IC cell delivery is an invasive procedure that requires a neurological surgery service, limiting the acute stroke patient population that would have access to this type of cell transplantation.

Better Safe than Sorry: Safety Profile of Stem Cells {#Sec4}
====================================================

In addition to demonstration of efficacy via behavioral testing, building a safety profile is an equally important gating item prior to proceeding to clinical trials of stem cell therapy. Along this line, EPCs have had a recent history of safety in the clinic. Clinical studies have been initiated to determine whether patients with lower numbers of EPCs are at an increased risk of atherosclerotic events, and whether patients with ischemic events may benefit from EPC administration \[[@CR68]\]. To date, clinical studies support the therapeutic potential of EPC transplantation; however, this assumption should be approached with much caution due to these studies being open label trials, observational and/or anecdotal accounts, and a limited number of patients.

Clinical studies of EPC in neurovascular disease are much very limited, with only three observational studies in patients with stroke. In 25 patients with an ischemic stroke, CD34+ cells peaked 7 days after stroke but generally reverted to baseline after 30 days \[[@CR69]\]. Interestingly, higher CD34+ cell levels at 30 days related to an increased number of infarcts on magnetic resonance imaging and also to worse cerebrovascular function, as measured with positron emission tomography scanning (cerebral metabolic rate of oxygen, and cerebral blood flow). On the other hand, decreased numbers of clusters of rapidly adhering cells were seen after stroke and in "stable cerebrovascular disease," compared with controls free of vascular disease \[[@CR24]\]. Cerebrovascular disease and higher age, in general, independently related to lower EPC numbers. These discrepancies in results may be from mismatched controls for patient age and/or the lack of methodological design for testing specific hypotheses on the causal role of EPC in cerebrovascular disease \[[@CR24]\].

The Changing Landscape of Cell-Based Therapeutic Targets: Intraparenchymal Versus Extraparenchymal Rescue of the Stroke Brain {#Sec5}
=============================================================================================================================

A major STEPS requirement is to demonstrate a specific set of phenotypic markers unique to the stem cell under investigation \[[@CR3]\]. EPCs were first isolated from human peripheral blood and express shared markers with HSCs, angioblasts, and receptors for vascular endothelial growth factor (VEGFR2/KDR) \[[@CR21]\]. Immunological surface markers and functional profiling via colony formation capacity have been utilized to determine EPC characteristics \[[@CR26]--[@CR29], [@CR70]\]. Various markers, such as CD31, VE-cadherin, E-selectin, von Willebrand factor and eNOS, have been employed to harvest EPCs \[[@CR21], [@CR26], [@CR28], [@CR70], [@CR71]\]. Equally solid evidence suggests that only CD34-positive EPCs isolated form umbilical cord blood or bone marrow posses the ability to differentiate into mature endothelial cells \[[@CR25], [@CR68], [@CR72]\]. Recent studies have employed the HSC specific AC133 surface marker to isolate EPCs \[[@CR26], [@CR29]\]. Double labeling with CD34 and VEGFR2 is the marker of choice for obtaining a highly homogenous population of EPCs \[[@CR26], [@CR29], [@CR73]\]. Functional profiling of EPCs is performed by counting the number of colonies formed after 7 days of culture. A colony consists of a central cluster of rounded cells with surrounding radiating thin, flat cells \[[@CR21], [@CR73]--[@CR75]\]. These colonies express many endothelial characteristics, including CD31, VEGFR2, and Tie-2 \[[@CR21], [@CR75]\]. Although characterization of EPCs in cell culture remains challenging, the unique properties of these cells as described by Finkel and co-workers \[[@CR68]\] may suffice as a starting point in delineating this novel BM cell population. This can be assessed by expression profiles, functional characteristics, and regenerative capacity, especially for promoting vasculogenesis and/or vascular homeostasis \[[@CR68]\].

Making the Correct STEPS in Designing the Experiments {#Sec6}
=====================================================

After confirming the stem cell phenotype, the optimal cell transplantation regimen should be examined. When designing an experimental model, the research design should closely approximate the envisioned clinical application. Optimization of cell dose, delivery route, and timing of administration are the three most crucial factors that needed to be determined in the laboratory. Based on the optimization results obtained in the laboratory, the next critical step is to determine whether these factors are feasible in the clinical setting. For instance, if stereotaxic transplantation of cells immediately following stroke was found to be a prerequisite for therapeutic benefit, then such intervention is obviously limited to patients who are able to reach a medical center with neurosurgical service. The delivery of cells via the periphery may likely require the need for chemotaxic signaling between the host ischemic brain and the transplanted cells, a scenario that may best benefit the acute or sub-acute phase of stroke rather than the stable, chronic stage when the chemokines/cytokines acting as cues for cell migration may not be that upregulated. With this in mind, EPCs are crucial for vasculogenesis and angiogenesis, thus potentially facilitating BBB repair post-ischemic injury. Accordingly, it is critical to elucidate the BBB breakdown cascades after stroke in order to identify the peak period when to initiate strategies designed to abrogate further vasculature damage and retard stroke progression. These factors must be considered when designing an experimental design for clinical translation.

To See is to Believe: Functional Readouts of Cell Transplants {#Sec7}
=============================================================

Next, STEPS requires that a battery of functional tests be in place to accurately define the therapeutic benefits of stem cells in stroke \[[@CR3]\]. A series of behavioral tests following ischemic injury and EPC transplantation will likely allow for closer approximation of clinical improvement associated with this cell therapy. Somatosensory and motor deficits are well documented in the rodent model of ischemic injury \[[@CR31], [@CR75]--[@CR78]\] and there is a growing trend toward the assessment of cognitive deficits. Alterations in cognitive behaviors can be assessed when cognitive areas of the brain are damaged by stroke, thus not all animals suffering from ischemic stroke, particularly the animals with localized damage sparing the hippocampus or specific areas of the basal ganglia, may not be the appropriate subjects for cognitive testing. Nonetheless, cognitive deficits may arise even when the hippocampus or other learning and memory areas are not affected by stroke, thus caution needs to be taken in delineating motor dysfunctions from cognitive impairments, as well as examining the brain region responsible for such cognitive alterations. Long term testing (i.e., at least 1 month) should be performed to elucidate whether functional recovery following cell therapy is stable or temporary. In contemplating with behavioral assessment of animals suffering stroke transplanted with EPCs, a novel aspect will be to test the hypothesis whether BBB repair can augment vasculogenesis and neurogenesis, among other neuroregenerative processes, in promoting functional recovery in stroke. Extensive behavioral testing after stroke and EPC transplantation is crucial in determining the efficacy of EPC transplantation, but also should facilitate a better understanding of mechanism of action of cell therapy (see further discussion below).

What Is in a Name? Mechanisms of Action Underlying Cell Therapy {#Sec8}
===============================================================

In recent years, the US FDA has shown keen interest in the mechanism of action underlying stem cell therapy. Until now, safety and efficacy are the main parameters required by the FDA for IND applications. Evidence suggests that stroke, at least the secondary cell death, is closely associated with a wave of immunological attack upon the brain and/or its vasculature. Whether EPCs abrogate this immunological response following stroke remains uncertain. Widespread inflammatory reactions caused by stroke may trigger a cascade of events, which alter the integrity of the BBB, resulting in migration of leukocytes into the central nervous system. Leukocyte transmigration across the BBB during stroke-mediated immune processes may influence inter-endothelial junctional complex function leading to damage to the vascular endothelium and BBB breakdown. The disruption or dysfunction of the BBB may be a key initial factor in stroke pathogenesis, a key component of Manaenko and colleague's \[[@CR79]\] hypothesis. EPCs may aid in ameliorating an immunological attack on the brain and its microvasculature by repairing the damaged BBB. Increasing the integrity of the BBB post-ischemic injury may aid in halting the progression of stroke pathogenesis, possibly leading to a better outcome. Thus, the study highlights the need for EPCs as transplantable cells for stroke therapy as the restoration of BBB integrity may play a critical role in preventing stroke progression.

The mechanisms of action underlying the beneficial effects of stem cells, in particular EPCs, are not fully understood. Two proposed mechanisms in which BM-derived stem cells are believed to exert therapeutic benefits are through cell replacement and trophic factor secretion. Although studies utilizing BM typically focused on cell replacement therapy, the secretion of trophic factors has become an increasingly important concept in the field of cell therapy. Trophic factors help promote angiogenesis and neurogenesis and may aid in rescuing the ischemic penumbra in stroke.

When translating cell therapy to the clinic, it is important to understand and identify the mechanisms of action in order to determine if there are possible safety risks to the patient. Cell signaling, secretion of growth factors, and graft-host synaptic connections may provide insights into stem cell-mediated repair of the stroke brain. Thus, targeting these pathways can then be used for the tracking and imaging of the transplanted cells. Imaging, in particular functional magnetic resonance imaging, has been utilized to determine graft response post-transplantation \[[@CR80], [@CR81]\]. These tools are becoming more widespread and frequent in determining the pathway, efficacy, and safety of cell transplantation in both the laboratory and the clinic.

Future Directions: Stem Cell Therapy Joining Forces with Small Molecule Treatment {#Sec9}
=================================================================================

The STEPS guidelines are an offshoot of the STAIR criteria. Here, we present a merger of STEPS and STAIR whereby a neuroprotective drug may be tested in the rigorous parameters of STAIR in tandem with stem cells using the STEPS guidelines. Combination therapies involving stem cells and drugs may provide a more robust stroke outcome over stand-alone treatments. As discussed above, tPA has a very narrow therapeutic window of 3 h after stroke onset. Furthermore, deleterious side effects of tPA, in particular bleeding and hemorrhagic transformation, can exacerbate stroke injury and counteract its benefits of reperfusion of the occluded artery. FDA-approved drugs such as albumin and minocycline (a tetracycline antibiotic) are only recently being explored in the clinic for their off-target, neuroprotective treatments in stroke. Because tPA is already an FDA-approved drug for stroke, finding strategies designed to extend its therapeutic window is a highly logical lab-to-clinic translation of experimental therapeutics in stroke. Hence, designing studies that dovetail on tPA's safety and efficacy profile, but also recognize the drug's limitations and adverse effects may prove to be advantageous for stroke therapy. In parallel, investigations into novel neuroprotective drugs that may be efficacious beyond the 3-hour window after stroke can also benefit many stroke patients. In 2002, Watterson and colleagues \[[@CR82]\] suggested, based on their earlier time course analysis \[[@CR83]\] of post-ischemia activity changes in the death associated protein kinase (DAPK) and the attenuation of neurologic sequelae resulting from treatment with DAPK inhibitors during the post-injury time windows of 6 h or later \[[@CR84]\], that DAPK may be a viable therapeutic target for stroke. Because of the significant unmet need in stroke for a delayed post-injury treatment schedules that might reduce longer-term neuronal loss, such neuroprotective regimens have the potential to contribute to improved outcomes in this disease. Using both in vitro and in vivo models of stroke, we recently obtained encouraging results revealing the robust neuroprotective effects of the protein kinase inhibitors targeting other events that peak during the 6--12-h post-ischemia time window. Significant reductions in stroke-induced histological and behavioral deficits were observed compared with animals suffering stroke that received a vehicle treatment alone. Shamloo and colleagues subsequently reported neuroprotective effects of the DAPK inhibitor developed by Watterson and coworker in both in vitro and in vivo stroke models using an experimental paradigm of DAPK inhibitor treatment initiated prior to and during stroke induction \[[@CR85]\]. More recently, Snyder and colleagues \[[@CR86]\] demonstrated that NMDA-induced excitotoxicity of cultured neurons deficient in DANGER, a partial MAB-21 domain-containing protein that binds directly to DAPK and inhibits DAPK catalytic activity, displayed significantly greater DAPK activity and increased cell death than wild-type control cells. They also reported that DANGER-deficient mice showed significantly more severe brain damage after acute injury than control mice. Therefore, both genetic and pharmacological approaches demonstrate that conditions characterized by inhibition of DAPK activity, either hours post-ischemia when DAPK activity reaches its peak of activity or coincident with ischemia induction, protect against subsequent neuronal loss. Altogether, a growing body of literature and ongoing studies indicate a pivotal role for DAPK in the physiological control of neuronal survival and pathophysiological role in neuronal death that can be attenuated by selective DAPK inhibition, thereby raising interest in addressing its potential as a novel target for stroke therapeutics. We envision that the timing of therapeutic treatments in the 6--9-h period after stroke induction corresponding to the peak time point of upregulation of DAPK enzyme activity, inflammatory genes and neurotoxic proteins as a viable therapeutic time window for treatments that attenuate events contributing to the exacerbation of secondary cell death in stroke. Being cognizant of the limited therapeutic window of tPA, finding an effective treatment beyond 3 h, such as the proposed DAPK inhibitor treatment, should greatly increase the target population of stroke patients who could benefit from this therapy. In the same vein, other neuroprotective drugs such as albumin and minocycline as well as the FDA-approved drug tPA, can be tested with stem cells using a combination of STEPS and STAIR criteria.

Conclusions {#Sec10}
===========

EPCs represent a population of cells critical for angiogenesis and vasculogenesis, thus they may play a critical role in BBB repair following stroke. The preclinical results have been encouraging, and the transplantation of stem cells, including EPCs, for stroke therapy is rapidly being translated into clinical trials \[[@CR87], [@CR88]\]. Over the last 5 years, recommendations to better guide the successful entry of stem cell therapy into the clinic have received continuing critical assessments from meetings involving leaders from academia, industry, NIH, and the FDA \[[@CR1]--[@CR3]\]. The mechanism of action underlying cell therapy remains to be fully determined. The optimal timing, route of injection, and dosage for EPC transplantation are also not fully understood. These persisting gaps in our knowledge should be seriously considered in order to achieve a clinically relevant estimate of the risk-to-benefit ratio of cell therapy for stroke. The initiation of clinical trials implementing EPC transplantation as a therapeutic regimen for stroke needs to be preceded by systematically designed translational preclinical studies to provide rigorous inquiry into the safety and efficacy of EPCs. Future studies are also planned in combining DAPK inhibitors and stem cell transplantation for stroke therapy. With the EPCs exerting indirect anti-inflammatory effects (via repair of the BBB thereby suppressing access of the inflammatory cells to the ischemic brain) and with small molecule inhibitors also affording anti-inflammatory modulation, the combination of these two types of novel treatments may synergistically arrest a major secondary cell death process associated with stroke.
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